{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:37:26Z","timestamp":1784824646845,"version":"3.55.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,13]]},"DOI":"10.7759\/cureus.78954","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T18:11:46Z","timestamp":1739470306000},"source":"Crossref","is-referenced-by-count":1,"title":["Intra-Class Interleukin-(IL)-17 Blocker Switching: Ixekizumab as a Solution for Secukinumab Non-responders in Secondary Biologic Failure in Psoriasis"],"prefix":"10.7759","author":[{"given":"Abhishek","family":"De","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Disha","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SK Shahriar","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.ijd_421_23","article-title":"Biologics and biosimilars in psoriasis","volume":"68","author":"Ahmed SS","year":"2023","unstructured":"Ahmed SS, De A, Das S, Manchanda Y. Biologics and biosimilars in psoriasis. Indian J Dermatol. 2023, 68:282-95. 10.4103\/ijd.ijd_421_23","journal-title":"Indian J Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.IJD_548_18","article-title":"Apremilast coadministered with secukinumab for safe and effective control of psoriasis with resultant reduction of maintenance dose of the biologic","volume":"64","author":"De A","year":"2019","unstructured":"De A, Das S, Dhoot D, Sarda A. Apremilast coadministered with secukinumab for safe and effective control of psoriasis with resultant reduction of maintenance dose of the biologic. Indian J Dermatol. 2019, 64:239-41. 10.4103\/ijd.IJD_548_18","journal-title":"Indian J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.IJD_311_17","article-title":"A case of cutaneous t-cell lymphoma, masquerading as psoriasis, was given etanercept and secukinumab: emphasizing the need for biopsy confirmation before starting biologics","volume":"62","author":"De A","year":"2017","unstructured":"De A, Raychaudhury T, Rajagopalan M, Sarda A, Sharma N. A case of cutaneous t-cell lymphoma, masquerading as psoriasis, was given etanercept and secukinumab: emphasizing the need for biopsy confirmation before starting biologics. Indian J Dermatol. 2017, 62:533-5. 10.4103\/ijd.IJD_311_17","journal-title":"Indian J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.ijd_939_20","article-title":"A joint consensus of rheumatologists and dermatologists on early detection and effective management of psoriatic arthritis: India's perspective","volume":"67","author":"Chatterjee M","year":"2022","unstructured":"Chatterjee M, Nayak C, De A, et al.. A joint consensus of rheumatologists and dermatologists on early detection and effective management of psoriatic arthritis: India's perspective. Indian J Dermatol. 2022, 67:479. 10.4103\/ijd.ijd_939_20","journal-title":"Indian J Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.IDOJ_113_21","article-title":"Systemic management of psoriasis patients in Indian scenario: an expert consensus","volume":"12","author":"Rajagopalan M","year":"2021","unstructured":"Rajagopalan M, Chatterjee M, De A, et al.. Systemic management of psoriasis patients in Indian scenario: an expert consensus. Indian Dermatol Online J. 2021, 12:674-82. 10.4103\/idoj.IDOJ_113_21","journal-title":"Indian Dermatol Online J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15666","article-title":"Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study","volume":"177","author":"Reich K","year":"2017","unstructured":"Reich K, Pinter A, Lacour JP, et al.. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol. 2017, 177:1014-23. 10.1111\/bjd.15666","journal-title":"Br J Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.01.037","article-title":"ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): a retrospective observational study on biologic drug survival in daily practice","volume":"74","author":"Vilarrasa E","year":"2016","unstructured":"Vilarrasa E, Notario J, Bordas X, L\u00f3pez-Ferrer A, Gich IJ, Puig L. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): a retrospective observational study on biologic drug survival in daily practice. J Am Acad Dermatol. 2016, 74:1066-72. 10.1016\/j.jaad.2016.01.037","journal-title":"J Am Acad Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14121169","article-title":"Efficacy and safety of intra-class switching from ixekizumab to secukinumab in patients with plaque psoriasis: a multicenter retrospective study","volume":"14","author":"Bernardini N","year":"2024","unstructured":"Bernardini N, Dattola A, Rossi R, et al.. Efficacy and safety of intra-class switching from ixekizumab to secukinumab in patients with plaque psoriasis: a multicenter retrospective study. J Pers Med. 2024, 14:10.3390\/jpm14121169","journal-title":"J Pers Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2015.10.009","article-title":"Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study","volume":"81","author":"Nakagawa H","year":"2016","unstructured":"Nakagawa H, Niiro H, Ootaki K. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2016, 81:44-52. 10.1016\/j.jdermsci.2015.10.009","journal-title":"J Dermatol Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3714","article-title":"Ixekizumab survival in heavily pretreated patients with psoriasis: a two-year single-centre retrospective study","volume":"100","author":"Sherman S","year":"2020","unstructured":"Sherman S, Zloczower O, Noyman Y, Amitay-Laish I, Hodak E, Pavlovsky L. Ixekizumab survival in heavily pretreated patients with psoriasis: a two-year single-centre retrospective study. Acta Derm Venereol. 2020, 100:adv00349. 10.2340\/00015555-3714","journal-title":"Acta Derm Venereol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12025","article-title":"Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal","volume":"167","author":"Spuls PI","year":"2012","unstructured":"Spuls PI, Hooft L. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol. 2012, 167:710-3; discussion 714-5. 10.1111\/bjd.12025","journal-title":"Br J Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-024-05722-1","article-title":"Biological therapy for psoriatic arthritis: current state and future perspectives","volume":"44","author":"Boboryko D","year":"2024","unstructured":"Boboryko D, Olejnik-Wojciechowska J, Baranowska M, Bratborska AW, Sk\u00f3rka P, Pawlik A. Biological therapy for psoriatic arthritis: current state and future perspectives. Rheumatol Int. 2024, 44:2711-25. 10.1007\/s00296-024-05722-1","journal-title":"Rheumatol Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/341427-intra-class-interleukin-il-17-blocker-switching-ixekizumab-as-a-solution-for-secukinumab-non-responders-in-secondary-biologic-failure-in-psoriasis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T18:11:48Z","timestamp":1739470308000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/341427-intra-class-interleukin-il-17-blocker-switching-ixekizumab-as-a-solution-for-secukinumab-non-responders-in-secondary-biologic-failure-in-psoriasis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.78954","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,13]]}}}